Compare Abeona Therapeutics Inc (ABEO) vs Arm Holdings plc (ARM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Arm Holdings plc — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Arm Holdings plc trades at $297.76 (market cap $320.88B). The key difference: Arm Holdings plc is far larger — about 859.5× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Arm Holdings plc nearer its low. Which is the better fit depends on your goals.
| ABEO | ARM | |
|---|---|---|
Market Cap | $373.32M | $320.88B |
Sector | Health | Technology |
52-Week High | $7.23 | $439.46 |
52-Week Low | $4.17 | $104.55 |
Enterprise Value | $228.22M | $317.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
ARM Holdings trades at $322.24, up 2.21% today but showing bearish technical momentum with key support at $317. The stock maintains strong fundamentals with 97.54% gross margins and consistent earnings beats, though valuation ratios remain elevated (P/E 379.11). Recent news highlights AI-driven growth in licensing and data center expansion, despite a 35% pullback from June 2026 peaks.
Outlook is mixed: robust AI demand and analyst optimism (74% buy ratings) support upside potential, but high valuation and technical weakness pose near-term risks. The consensus price target of $321.65 aligns with current levels, suggesting cautious optimism amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Arm Holdings plc
Arm Holdings designs the architecture for high-performance, energy-efficient processors used in nearly all smartphones and millions of other devices. Its intellectual property powers global computing from mobile to AI.
Read more on ARM →
